Originally published by our sister publication Infectious Disease Special Edition
By Marie Rosenthal
The investigational combination of lenacapavir with two broadly neutralizing antibodies (bNAbs) would make twice-yearly HIV treatment possible.
A new study found the combination to be generally well tolerated and highly effective in virologically suppressed participants living with HIV, who were sensitive to the antibodies, which lasted for six months, according to data presented at CROI